Sales of Anticoagulant Reversal Drugs to Soar in North America, While APAC Sees Moderate Growth
Favourable regulatory scenario, especially in developed economies of North America and Europe, has inadvertently created a highly conducive environment for the growth of the anticoagulant reversal drugs market.
However, steep prices of anticoagulant reversal drugs will result in moderate sales in price-sensitive countries of APAC and MEA.
Taking a cue from this high-cost concern, regional and local players are looking at increasing their presence in the anticoagulant reversal drugs market through the introduction of generic drugs.
Their global counterparts, however, are increasing investments towards the development of blockbuster drugs.
All-in-all, the anticoagulant reversal drugs market is projected to offer equal growth opportunities to global, regional, and local players, given the fragmented nature of the market space.
Popularity of Idarucizumab to Lose Vigour to Andexxa
Sales of Idarucizumab increased 19% Y-o-Y in 2019 over 2018. However, according to the estimation of a seasoned analyst at Fact.MR, year-over-year sales of the same drug will witness a sharp decrease of 11% in 2026 over 2025.
This drug achieved immediate traction in the anticoagulant reversal drugs market, owing to the absence of an equivalent reversal agent.
The downward sales curve traced by Idarucizumab can be attributable to the increasing popularity of Andexxa, which received approval from the U.S. Food and Drug Administration in 2018.
There has been a steep increase in the preference for Andexxa over Idarucizumab, given the recognition received by the novel reversal agent as an orphan drug.
In the future, the popularity of this drug is projected to witness exponential growth, as there is an absence of effective drugs in the anticoagulant reversal drugs market.
Introduction of New Technology Add-on Payment to Underpin Sales
As the challenge regarding the limited penetration of effective drugs came into light, cost-prohibitive nature of reversal agents was found to have a negative influence on their sales.
Governments of developed countries launched a new payment system - new technology add-on payment (NTAP) - to promote the adoption of new and expensive drugs.
The reimbursement plan, in turn, is projected to underpin the expenses of patients and drive profitability to the anticoagulant reversal drugs market during the forecast period.
Under this plan, the Praxbind drug is eligible for availing complete reimbursement in England, Wales, and Ireland, without the need for full approval by Health Technology Appraisal authorities.
On the backdrop of favourable reimbursement plans present in the anticoagulant reversal drugs market, a wide base of patients is expected to avail these benefits, and, in turn, amplify sales prospects.
Market Players Strive to Meet Unmet Clinical Demands
The application of reversal agents has witnessed a marked increase in recent times, in life-threatening conditions or cases with uncontrolled bleeding.
Manufacturers in the anticoagulant reversal drugs market are sensing a rise in demand and navigating their research & development endeavours to bridge the underlying gaps present in these therapeutics.
This is leading to a robust pipeline for anticoagulant reversal drugs, especially in Europe and North America, given the high concentration of leading players in these regions.
In addition, there has been an increase in governments’ financial aid towards promoting the production of effective therapeutics, which is further paving way for the introduction of novel drugs in the anticoagulant reversal drugs market.
Fast-track approval of blockbuster drugs is enabling players in the anticoagulant reversal drug market to achieve faster time-to-market, which is predicted to extend the scope of the market.
Avail customized purchase options for your needs
Sales through Hospital Pharmacies will Remain High in North America
The evolving landscape is adding new revenue streams for the anticoagulant reversal drugs market; however, hospital pharmacies are projected to account for ~65% of the total sales by 2026.
The increasing prevalence of atrial fibrillation, intracranial haemorrhages, and gastrointestinal haemorrhages is projected to boost the demand for anticoagulant reversal drugs.
North America is expected to close a majority of sales through anticoagulant reversal drugs. The region is home to a large number of hospitals offering quality healthcare services.
With the growing number of surgeries, the sales of anticoagulant reversal drugs through hospital pharmacies are on the rise. In addition, recent times have witnessed a surge in the number of outpatient care centres and ambulatory surgical centres, which is projected to strengthen the demand for anticoagulant reversal drugs.
Anticoagulant Reversal Drugs Market - Assessment of Key Segments
Authors of the report have segmented the anticoagulant reversal drugs market into key categories in order to study the market at a microscopic level. The key segments considered while bifurcating the anticoagulant reversal drugs market include:
Besides magnifying focus on the crucial segments, this exclusive study also offers information on the anticoagulant reversal drugs market at a country level, to identify the underlying opportunities available for players in the anticoagulant reversal drugs market for the forecast period. Among all the estimated data, the report also includes Y-o-Y growth projections, which can help market players in comprehending the precise trajectory at which the anticoagulant reversal drugs market has been growing.
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.